Skip to search formSkip to main contentSkip to account menu

Anal Canal Neuroendocrine Carcinoma

Known as: Anal Canal NEC G3, Anal Neuroendocrine Carcinoma, Anal Canal NEC 
An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the anal canal. The mitotic count… 
National Institutes of Health

Related topics

Related topics

10 relations
Anal canalAnal mucosaAnusEndocrine system

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3.
Review
2019
Review
2019
Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): A multicenter retrospective review.
321 Background: G3 NENs are aggressive, and optimal systemic treatment is unclear. Temozolomide (TEM)-based regimens have been… 
2014
2014
First report of chronic hepatitis E in renal transplant recipients in Portugal.
Hepatitis E virus (HEV) infection can be responsible for chronic hepatitis in immunocompromised patients, and can rapidly evolve… 
2012
2012
ANALISIS ALOKASI DANA CORPORATE SOCIAL RESPONSIBILITY SERTA PELAPORAN SUSTAINABILITY REPORT BERDASARKAN GLOBAL REPORTING INITIATIVE (GRI G3) DI PT. PEMBANGKITAN JAWA BALI
This study tries to Analysis for allocation of Corporate Social Responsibility’s funds and reporting of sustainability report… 
2012
2012
Wytyczne G3 i G3.1 Global Reporting Initiative dotyczące raportowania kwestii zrównoważonego rozwoju – analiza porównawcza
2010
2010
Management of protracted active labor with nipple stimulation: a viable tool for midwives?
2009
2009
Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma.
5037^ Background: RAD001 (everolimus) and sunitinib (SUTENT) both have activity in metastatic renal cell carcinoma (mRCC… 
2006
2006
Survival and progression in high grade tumour subset of G2 and G3 pT1 bladder transitional cell carcinoma.
2006
2006
Tumores de vejiga pT0 tras cistectomía radical: análisis de nuestra serie
1989
1989
CA-50 as tumour marker in transitional bladder carcinoma.
Monoclonal antibody CA-50 is a useful tumour marker in gastrointestinal carcinoma. We report an assessment of its value in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)